- Home
- DMRA vs INVA Comparison
DMRA vs INVA Comparison
Compare DMRA & INVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DMRA | INVA |
|---|---|---|
| Founded | 2011 | 1996 |
| Country | United States | United States |
| Employees | 7 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.7B |
| IPO Year | 2020 | 2000 |
Fundamental Metrics
Financial Performance| Metric | DMRA | INVA |
|---|---|---|
| Price | $24.85 | $23.55 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $46.00 | $32.80 |
| AVG Volume (30 Days) | 217.1K | ★ 536.8K |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 816.67 |
| EPS | N/A | ★ 3.30 |
| Revenue | N/A | ★ $217,217,000.00 |
| Revenue This Year | N/A | $8.95 |
| Revenue Next Year | N/A | $12.65 |
| P/E Ratio | ★ N/A | $7.10 |
| Revenue Growth | N/A | ★ 62.63 |
| 52 Week Low | $16.50 | $16.52 |
| 52 Week High | $28.76 | $25.15 |
Technical Indicators
Market Signals| Indicator | DMRA | INVA |
|---|---|---|
| Relative Strength Index (RSI) | 46.18 | 53.25 |
| Support Level | $23.65 | $23.28 |
| Resistance Level | $28.00 | $25.15 |
| Average True Range (ATR) | 2.13 | 0.63 |
| MACD | -0.14 | -0.08 |
| Stochastic Oscillator | 28.16 | 45.30 |
Price Performance
Historical ComparisonAbout DMRA Damora Therapeutics Inc. Common Stock
Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.
About INVA Innoviva Inc.
Innoviva Inc is a company with a portfolio of royalty healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Trelegy, and others.